Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Sustained-Release Injectable Tacrolimus in Healthy Subjects
NCT03626714Phase 1Completed
- Sponsor
- Auritec Pharmaceuticals, Inc.
- Start
- Oct 2018
- Primary completion
- Jan 2019
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tacrolimus in organ transplant rejection, sponsored by Auritec Pharmaceuticals, Inc. Primary endpoints: Number of Subjects That Experienced Treatment-related Adverse Events at 60 days, Drug Concentrations in Blood Samples at Individual Time-points at 60 days and 4 more. Started Oct 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
organ transplant rejection
Beyond the preview
Go deeper on NCT03626714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626714.